Full metadata record
DC Field | Value | Language |
---|---|---|
dc.creator | Rodriguez-Ruiz, M.E. (María Esperanza) | - |
dc.creator | Marquez-Rodas, I. (Iván) | - |
dc.creator | Longo, F. (Federico) | - |
dc.creator | Calles, A. (Antonio) | - |
dc.creator | Ponce, S. (Santiago) | - |
dc.creator | Jove, M. (Maria) | - |
dc.creator | Rubio, B. (Belén) | - |
dc.creator | Perez-García, J. (José) | - |
dc.creator | Gómez-Rueda, A. (Ana) | - |
dc.creator | López-Tarruella, S. (Sara) | - |
dc.creator | Ponz-Sarvise, M. (Mariano) | - |
dc.creator | Alvarez, R. (Rosa) | - |
dc.creator | Soria, A. (Ainara) | - |
dc.creator | de Miguel, E. (Enrique) | - |
dc.creator | Ramos-Medina, R. (Rocío) | - |
dc.creator | Castañon, E. (Eduardo) | - |
dc.creator | Gajate, P. (Pablo) | - |
dc.creator | Sempere-Ortega, C. (Cayetano) | - |
dc.creator | Jiménez-Aguilar, E. (Elisabeth) | - |
dc.creator | Aznar, M.A. (María Ángela) | - |
dc.creator | Calvo, A. (Aitana) | - |
dc.creator | Lopez-Casas, P. (Pedro) | - |
dc.creator | Martin-Algarra, S. (Salvador) | - |
dc.creator | Martín-Echarri, M. (Miguel) | - |
dc.creator | Tersago, D. (Dominique) | - |
dc.creator | Quintero, M. (Marisol) | - |
dc.creator | Melero, I. (Ignacio) | - |
dc.date.accessioned | 2024-02-09T12:00:57Z | - |
dc.date.available | 2024-02-09T12:00:57Z | - |
dc.date.issued | 2020 | - |
dc.identifier.citation | Rodriguez-Ruiz, M.E. (María Esperanza); Marquez-Rodas, I. (Iván); Longo, F. (Federico); et al. "Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti–PD-1 for patients with anti–PD-1–refractory tumors". Science Translational Medicine. 12 (565), 2020, 1 - 11 | es_ES |
dc.identifier.uri | https://hdl.handle.net/10171/68983 | - |
dc.description.abstract | Intratumoral therapies, especially Toll-like receptor agonists, can trigger both the innate and adaptive immune systems. BO-112 is a nanoplexed form of polyinosinic:polycytidylic acid (poly I:C) that induces local and systemic immunotherapeutic effects in mouse models. In a multicenter phase 1 clinical trial, repeated intratumoral administrations of BO-112 induced an increase in tumor cell necrosis and apoptosis, as well as augmented immune reactivity according to gene expression profiling. The first three cohorts receiving BO-112 as a monotherapy resulted in a recommended dose of 1 mg that could be safely repeated. Two grade 3 to 4 adverse reactions in the form of reversible thrombocytopenia were reported. In a fourth cohort of 28 patients with tumors that had primary resistance to anti–programmed cell death protein–1 (PD-1), the combination of intratumoral BO-112 with nivolumab or pembrolizumab was also well tolerated, and 3 patients (2 with melanoma and 1 with renal cell carcinoma) achieved partial responses, with 10 more patients having stable disease at 8 to 12 weeks. Thus, local BO-112 combined with a systemic anti–PD-1 agent might be a strategy to revert anti–PD-1 resistance | es_ES |
dc.language.iso | eng | es_ES |
dc.rights | info:eu-repo/semantics/embargoedAccess | * |
dc.subject | Intratumoral therapies | es_ES |
dc.subject | BO-112 | es_ES |
dc.subject | Polycytidylic acid | es_ES |
dc.subject | Programmed cell death protein–1 (PD-1) | es_ES |
dc.title | Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti–PD-1 for patients with anti–PD-1–refractory tumors | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.relation.publisherversion | https://www.science.org/doi/10.1126/scitranslmed.abb0391?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed | es_ES |
dc.editorial.note | © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Work | es_ES |
dadun.citation.endingPage | 11 | es_ES |
dadun.citation.number | 565 | es_ES |
dadun.citation.publicationName | Science Translational Medicine | es_ES |
dadun.citation.startingPage | 1 | es_ES |
dadun.citation.volume | 12 | es_ES |
Files in This Item:
Statistics and impact
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.